CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Key facts
- Who runs it
- Hellenic Institute for the Study of Sepsis
- Where
- Greece15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 252 people, planned
- Started
- 16 Sept 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Placebo
- clarithromycin
- Record updated
- 3 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (28)Hide the full registry criteria
Who can take part
- Age equal to or above 18 years
- Patients of either gender
- Written informed consent provided by the patient. For patients without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation
- Negative (blood or urinary) pregnancy test for female patients of reproductive age
- For female patients of reproductive age, willingness to use highly effective contraception during and seven days after the administration of the IMP
- Presence of Community-acquired pneumonia (CAP)
- Presence of sepsis as defined by the Sepsis-3 classification criteria (at least 2 points increase of the total SOFA-1 score from the baseline score of the specific patient). The SOFA score which will be used for the definition of sepsis has recently been renamed SOFA-1
- Absolute lymphocyte count (ALC) less than 1000/mm³
Who cannot take part
- Unwillingness to receive contraception during and seven days after the administration of the IMPstudy drug (for Female patients)
- Solid organ or bone marrow transplantation
- Corticosteroid oral or intravenous intake greater than 0.4mg/kg of equivalent prednisone daily over the last 15 days or other immunosuppressive therapy. However, corticosteroids received as adjunctive treatment for the current septic/infectious episode are allowed
- Previous participation in the CLASSIFY study
- Known active neoplasms or other conditions unrelated to sepsis that compromise short-term survival less than 6 months
- Medical history of allergy to macrolides
- Medical history of torsades de pointes arrhythmia
- Severe hepatic failure in combination with renal impairment
- Known HIV infection with known CD4 cell count <200/mm³
- QTc interval at rest in the ECG ≥500 msec or history of known long QT syndrome
- Concomitant use of medicinal products contraindicated with clarithromycin, including CYP3A substrates associated with QT prolongation (e.g., astemizole, cisapride, domperidone, pimozide, terfenadine, ivabradine), ergot alkaloids (e.g., ergotamine, dihydroergotamine), oral midazolam, HMG-CoA reductase inhibitors primarily metabolised by CYP3A4 (e.g., lovastatin, simvastatin), colchicine, ticagrelor, and ranolazine. This criterion applies to all medicinal products within these classes, not only the specific examples listed, in accordance with the SmPC for clarithromycin. Patients may be enrolled provided that such medications are discontinued prior to or at the time of trial participation. Given their short half-life, no wash-out period is required
- Age below 18 years
- Denial of written informed consent
- Pregnancy (confirmed by blood or urinary pregnancy test) or lactation for female patients
- Intake of a biological agent in the last month
- Neutropenia < 500/mm³
- Intake of any macrolide for the current episode of CAP under study
- Severe hypokalemia or hypomagnesemia; patients may be enrolled once these electrolyte abnormalities are corrected
- Any contradictions for macrolide uptake
- Participation in any other interventional trial within the last 30 days
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sepsis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new infection, including worsening or recurrence of the initial CAP episode, new infections at other sites, and secondary sepsis during the 28-day follow-up period. Secondary objectives are to investigate the impact of clarithromycin on mortality, sepsis response, type of secondary infection, time to antimicrobial escalation, hospital readmission, quality of life, cost-effectiveness, and biomarkers of sepsis-induced immunoparalysis.
Read full original descriptionShow less
Researchers will compare clarithromycin plus standard-of-care antibiotic therapy to placebo plus standard-of-care antibiotic therapy.
Participants will:
* Receive clarithromycin or placebo, administered orally or intravenously, in addition to standard-of-care antibiotic therapy for up to 7 days. * Be evaluated during treatment and follow-up through Day 28, with additional assessment of mortality, hospital readmission, and health status through Day 90.
The 2 groups in the trial
- Standard-of-care (SoC) and placeboPlacebo, for comparison
In the case of IV placebo medication, patients receive water for injection at a volume of 10ml diluted to a final volume of 250 ml dextrose in water 5%. The duration of the infusion is 1 hour and treatment is given every 12 hours daily for 7 days. In the case of oral placebo medication, this is given as oral tablets every 12 hours once for 7 days. Step-down from IV to oral medication, respectively, is permitted.
Treatment: Placebo
- Standard-of-care (SoC) and clarithromycinExisting treatment, for comparison
In the case of IV medication, patients receive 500 mg of clarithromycin diluted with water for injection at a volume of 10ml and further diluted to a final volume of 250 ml dextrose in water 5%. The duration of the infusion is 1 hour and treatment is given every 12 hours daily for 7 days. In the case of oral medication, this is given as clarithromycin IR 500mg every 12 hours for 7 days. Step-down from IV to oral medication, respectively, is permitted.
Treatment: clarithromycin
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from NCT07834346, who can take part
- Record updated
- 3 November 2026